The chemical and pharmaceutical group is in the sights of investors who are demanding changes.
(Photo: Reuters)
Dusseldorf, Frankfurt A possible Alliance of influential investors challenges the Bayer Group’s Board of Management and Supervisory Board in terms of strategy and leadership. According to financial circles, the activist investor Bluebell is gathering allies after joining the Leverkusen group in order to enforce his demands.
Since it became known that Bluebell was involved with Bayer, many investors had approached the activist, a person familiar with the matter told the Handelsblatt. These investors have “the same thoughts” and complained about the weak share price.
Bluebell calls according to the information a quick replacement of the CEO position with an external candidate. Bayer CEO Werner Baumann’s contract runs until April 2024. The investor is also demanding changes in the supervisory board and the splitting up of the group. A first step should be the spin-off of the business with non-prescription drugs around the Aspirin brand.
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Further
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Further